Such a therapy could be further combined with the anti-PD-1-mediated immune checkpoint blockade therapy, leading to increased populations of the CD4+ and CD8+ T cells and the M1 macrophages but reduced populations of the Treg cells and the M2 macrophages in tumor tissues. The gene discussed is PDCD1; the disease is neoplasm.